Observational study on treatments for relapsed multiple myeloma
Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
This study looks at how well certain approved treatments work for adults with relapsed multiple myeloma who have already tried specific therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, PV) |
| Trial ID | NCT06541860 on ClinicalTrials.gov |
What this trial studies
This study is a multicenter observational analysis focusing on patients with relapsed and refractory multiple myeloma who have previously undergone treatment with anti-CD38 monoclonal antibodies and immunomodulatory drugs (IMIDs). It aims to evaluate the effectiveness of on-label treatment regimens in these patients. The study includes both retrospective and prospective data collection to assess patient outcomes and treatment responses. Participants must be at least 18 years old and provide informed consent for data review.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with relapsed and refractory multiple myeloma who have received prior therapy with anti-CD38 monoclonal antibodies and IMIDs.
Not a fit: Patients who are not willing to consent to the review of clinical data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective treatment strategies for patients with relapsed multiple myeloma.
How similar studies have performed: Other studies have shown success with similar observational approaches in understanding treatment outcomes for multiple myeloma, indicating this study builds on established methodologies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Phase I * Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme * Patients aged ≥ 18 years * Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data Phase II * Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes * Patients aged ≥ 18 years * Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data Exclusion Criteria: * Patients not willing to consent to review of clinical data
Where this trial is running
Pavia, PV
- Irccs San Matteo Pavia — Pavia, Pv, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.